...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer biology & therapy >Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.
【24h】

Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.

机译：胰高血糖素/胰岛素比是新发糖尿病患者胰腺癌的潜在生物标志物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, with an overall 5-year survival rate of less than 5%. This dismal prognosis is largely due to the advanced stage of the disease at presentation, i.e., the late diagnosis. Therefore, early detection would have the potential to significantly improve the overall prognosis of PDAC patients. Diabetes mellitus (DM) has a high prevalence in PDAC patients and is frequently of new onset. The aim of this study was to analyze whether DM can be utilized as an early disease marker in PDAC. Quantitative RT-PCR analysis and immunohistochemistry for insulin and glucagon was performed in 22 PDAC and 16 normal pancreas tissues. Blood samples of 66 patients suffering from PDAC, 35 DM type 2 patients, and 29 healthy donors were analyzed for insulin, glucagon, C-peptide and glucose levels. Quantitative RT-PCR showed a two-fold increase of the glucagon/insulin ratio in pancreatic cancer tissues in comparison to the normal pancreas. By immunohistochemistry a shift in the expression pattern of glucagon and insulin, i.e., a higher glucagon/insulin ratio was found in PDAC associated islets compared to islets in the normal pancreas. Fasting insulin levels in PDAC patients were lower compared to DM patients. The calculated serum glucagon/insulin ratio was significantly different between PDAC and DM patients. At a cut-off of 7.4 ng/mU glucagon/insulin, pancreatic cancer induced new-onset DM could be discriminated from type 2 DM with 77% sensitivity and 69% specificity. In conclusion, the suggested serum glucagon/insulin ratio showed significant differences in patients with PDAC related DM and type 2 DM. Therefore, this analysis might help to identify PDAC in patients with new-onset DM in the age group at risk. Larger clinical trials have to confirm these findings.
机译：胰腺导管腺癌（PDAC）是最具侵略性的恶性肿瘤之一，其5年总生存率不到5％。这种糟糕的预后很大程度上是由于疾病的晚期阶段，即晚期诊断。因此，早期发现将有可能显着改善PDAC患者的总体预后。糖尿病（DM）在PDAC患者中患病率很高，并且经常是新发病例。这项研究的目的是分析DM是否可以用作PDAC中的早期疾病标记。在22个PDAC和16个正常胰腺组织中进行了胰岛素和胰高血糖素的定量RT-PCR分析和免疫组化。分析了66名患有PDAC的患者，35名DM 2型患者和29位健康供体的血液样本中的胰岛素，胰高血糖素，C肽和葡萄糖水平。与正常胰腺相比，定量RT-PCR显示胰腺癌组织中胰高血糖素/胰岛素比率增加了两倍。通过免疫组织化学，胰高血糖素和胰岛素的表达模式发生了变化，即与正常胰腺中的胰岛相比，在PDAC相关的胰岛中发现了更高的胰高血糖素/胰岛素比。与DM患者相比，PDAC患者的空腹胰岛素水平较低。在PDAC和DM患者之间，计算得出的血清胰高血糖素/胰岛素比率存在显着差异。在7.4 ng / mU胰高血糖素/胰岛素的临界值下，可以将胰腺癌诱导的新发DM与2型DM区别开，敏感性为77％，特异性为69％。总之，建议的血清胰高血糖素/胰岛素比率在PDAC相关DM和2型DM患者中显示出显着差异。因此，该分析可能有助于确定处于危险年龄组的新发DM患者的PDAC。较大的临床试验必须证实这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号